| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $184.7M | +54.6% |
| SG&A Expense | $31.7M | -8.4% |
| Operating Income | -$216.4M | -40.5% |
| Pre-tax Income | -$206.7M | -249.6% |
| Income Tax | $0 | — |
| Net Income | -$206.7M | -49.6% |
| EPS (Basic) | -$1.34 | -32.7% |
| EPS (Diluted) | -$1.34 | -32.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $162.1M | +227.4% |
| Current Assets | $242.2M | -23.5% |
| Total Assets | $277.6M | -20.7% |
| Current Liabilities | $42.6M | +39.7% |
| Total Liabilities | $65.9M | +15.7% |
| Stockholders' Equity | $211.6M | -27.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$186.4M | -57.9% |
| Capital Expenditures | $137K | +813.3% |
| Investing Cash Flow | $190.1M | +186.9% |
| Financing Cash Flow | $108.9M | -32.5% |
| Free Cash Flow | -$186.5M | -58.0% |